Lensing A W, Prandoni P, Prins M H, Büller H R
Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
Lancet. 1999 Feb 6;353(9151):479-85. doi: 10.1016/s0140-6736(98)04298-6.
Deep-vein thrombosis is an important complication of several inherited and acquired disorders, but may also occur spontaneously. Prevention of recurrent venous thrombosis and pulmonary embolism is the main reason for accurate diagnosis and adequate treatment. This seminar discusses only symptomatic deep-vein thrombosis. The diagnosis can be confirmed by objective tests in only about 30% of patients with symptoms. Venous thromboembolic complications happen in less than 1% of untreated patients in whom the presence of venous thrombosis is rejected on the basis of serial ultrasonography or ultrasonography plus either D-dimer or clinical score. Initial anticoagulant treatment (intravenous or subcutaneous heparin) should continue until oral anticoagulant treatment, started concurrently, increases the international normalised ratio above 2.0 for more than 24 h. The optimum duration of oral anticoagulant treatment is unresolved, but may be guided by the presence of temporary or persistent risk factors or presentation with recurrent venous thromboembolism.
深静脉血栓形成是多种遗传性和获得性疾病的重要并发症,但也可能自发发生。预防复发性静脉血栓形成和肺栓塞是准确诊断和充分治疗的主要原因。本次研讨会仅讨论有症状的深静脉血栓形成。只有约30%有症状的患者可通过客观检查确诊。在根据系列超声检查或超声检查加D-二聚体或临床评分排除静脉血栓形成的未治疗患者中,静脉血栓栓塞并发症发生率低于1%。初始抗凝治疗(静脉或皮下注射肝素)应持续至同时开始的口服抗凝治疗使国际标准化比值升高至2.0以上并持续超过24小时。口服抗凝治疗的最佳持续时间尚未确定,但可能由临时或持续危险因素的存在或复发性静脉血栓栓塞的表现来指导。